Company News

June 2017 - Dendritic Cell (APC) and Autologous T-Cell Response (White Paper)

Xeno Diagnostics has added a mixed lymphocyte tumor cell assay to our list of services. The mixed lymphocyte tumor cell (MLTuC) is a method for generating T-lymphocytes that are cytotoxic to specific tumor cells. This assay offers a means to screen various pharmacological agents for their ability to enhance T-cell cytotoxicity to specific neoplasms. Click here to download.

 

December 7, 2016 - Xeno has won its 4th consecutive Laboratory Excellence Award following its most recent regulatory inspection.

Xeno Diagnostics has received an award for Laboratory Excellence following its most recent COLA inspection, making this the fourth consecutive inspection for Xeno to receive this award. Xeno has met all criteria for Laboratory Accreditation by COLA, a national healthcare accreditation organization. Accreditation is earned only by laboratories that apply rigid standards of quality in day-to-day operations, demonstrate continued accuracy in the performance of proficiency testing, and pass a rigorous on-site laboratory survey with no citations....read more

 

February 9, 2016 - Modfied glycan models of pig-to-human xenotransplantation do not enhance the human-anti-pig T cell response.

Genetically modified porcine models of pig-to-human xenotransplantation offer the most immediate answer to a growing shortage of available solid organs. Recently a modified porcine glycan model has been discovered that reduces human antibody binding to levels comparable with allograft standards. As this background provides an answer to the problem of acute humoral xenograft rejection (AHXR), it is important to consider the impact these modifications have on...read more

 

March 22, 2015 - Full Length Single Chain, A Novel gp120-CD4 Fusion HIV Subunit Vaccine, Does Not Cause a Deleterious Autoimmune CD4 Response in Cynomolgus Macaques

Full length single chain (FLSC) is a novel HIV vaccine that presents conserved CD4i epitopes on HIV envelope. The constrained structure is achieved with single chain complexes of gp120 and CD4 fragments. FLSC elicits cross-reactive antibodies and heterologous protection against SHIV/SIV in three independent...read more

 

December 17, 2014 - Xeno Diagnostics Receives 3rd Award for Laboratory Excellence

Xeno Diagnostics has again received an award for Laboratory Excellence following its most recent COLA inspection. Xeno has met all criteria for Laboratory Accreditation by COLA, a national healthcare accreditation organization. Accreditation is earned only by laboratories that apply rigid standards of quality in day-to-day operations, demonstrate continued accuracy in the performance of proficiency testing, and pass a rigorous on-site laboratory survey...read more

 

September 10, 2014 - Xeno Diagnostics Adds Dr. Daniel Wierda as Director of Research and Development

Xeno Diagnostics, LLC, announced today that Dr. Daniel Wierda has joined Xeno as their new Director of Research and Development. Dan brings with him a great depth of experience in the area of immunotoxicology and cell-based assays. Prior to joining Xeno, Dan worked for 22 years at Eli Lilly and Company as a research scientist and toxicologist...read more

 

February 15, 2013 - Xeno Diagnostics, LLC Receives Award for Laboratory Excellence

Xeno Diagnostics, LLC has met all criteria for Laboratory Accreditation by COLA, a national healthcare accreditation organization. Accreditation is given only to laboratories that apply rigid standards of quality in day-to-day operations, demonstrate continued accuracy in the performance of proficiency testing, and pass a rigorous on-site laboratory survey...read more

 *required field